<rt id="gcqaw"></rt>
返回
公司介紹
董事會(huì)
管理團(tuán)隊(duì)
合作伙伴
企業(yè)榮譽(yù)
專(zhuān)利布局
納基奧侖賽
認(rèn)證醫(yī)療機(jī)構(gòu)名單
創(chuàng)新支付
研發(fā)管線
學(xué)術(shù)發(fā)表
公司新聞
產(chǎn)品新聞
媒體報(bào)道
企業(yè)文化
招賢納士
Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy
Phase 1 Results of CNCT19: CD19 CAR Constructed of a New Anti-CD19 Chimeric Antigen Receptor in Relapsed or Refractory Acute Lymphoblastic Leukemia.
The Risk of Hepatitis B Reactivation Is Controllable in Patients with Concomitant Hepatitis B Virus Infection during Chimeric Antigen Receptor T-Cell Therapy
查看更多 +
010-65960020
